Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma

被引：0

作者：

Martin, Thomas ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Mikhael, Joseph ^{[3
]}

Yong, Kwee ^{[4
]}

Capra, Marcelo ^{[5
]}

Facon, Thierry ^{[6
]}

Hajek, Roman ^{[7
,8
]}

Spicka, Ivan ^{[9
]}

Casca, France ^{[10
]}

Mace, Sandrine ^{[11
]}

Risse, Marie-Laure ^{[12
]}

Moreau, Philippe ^{[13
]}

机构：

[1] Univ Calif San Francisco, Dept Hematol, San Francisco, CA USA

[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[3] Translat Genom Res Inst, City Hope Canc Ctr, Phoenix, AZ USA

[4] Univ Coll Hosp, Dept Hematol, London, England

[5] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil

[6] Lille Univ Hosp, Dept Hematol, Lille, France

[7] Univ Ostrava, Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[8] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[9] Charles Univ & Gen Hosp, Ist Fac Med, Dept Hematol, Dept Med, Prague, Czech Republic

[10] Ividata Life Sci Contracted Sanofi, Levallois Perret, France

[11] Sanofi R&D Translat Med, Chilly Mazarin, France

[12] Sanofi R&D, Vitry Sur Seine, France

[13] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

MM; IKEMA; isatuximab; multiple myeloma; progression-free survival; Phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-064

引用

页码：S403 / S404

页数：2

共 50 条

[21] Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study
Ishida, Tadao
Ito, Shigeki
Tanaka, Junji
Uchiyama, Michihiro
Kawano, Yawara
Moreau, Philippe
Martin, Thomas
Risse, Marie-Laure
Tada, Keisuke
Suzuki, Kenshi
Ishizawa, Kenichi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (12) : 1446 - 1449
[22] Combination Therapy with Isatuximab in relapsed multiple Myeloma Superior progression-free Survival and clinically meaningful Depth of Response
Ruedesheim, Sabine M.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
[23] Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial
Pelham, Robert J.
Hu, Xuguang
Moreau, Philippe
Oriol, Albert
Quach, Hang
Kovacsovics, Tibor
Keats, Jonathan J.
Feng, Shibao
Kimball, Amy S.
Dimopoulos, Meletios A.
BLOOD, 2017, 130
[24] A Phase 3 Study of Carfilzomib and Dexamethasone (Kd) in Patients With Relapsed and Refractory Multiple Myeloma (MM) in China
Du, Juan
Fang, Baijun
Li, Jian
Jin, Jie
Wang, Shunqing
Zou, Dehui
Cai, Zhen
Wang, Hongxiang
Hu, Jianda
Li, Wei
Fu, Chengcheng
Shao, Zonghong
Xia, Zhongjun
Liu, Peng
Niu, Ting
Tang, En-Tzu
Kimball, Amy
Hou, Jian
Chen, Wenming
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E267 - E268
[25] A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
Richardson, Paul G.
Amatangelo, Michael
Berenson, James R.
Cerchione, Claudio
Dimopoulos, Meletios A.
Hansen, Charlotte Toftmann
Hwang, Soo Jeong
Koo, Phillip
Kuroda, Junya
Oriol, Albert
Orlowski, Robert Z.
Quach, Hang
Raab, Marc S.
Rocci, Alberto
Wang, Yue
White, Darrell
Yu, Brian
Zhou, Zehua
Katz, Jessica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] CARFILZOMIB AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL AND RESPONSE RATES VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS (PTS) WITH RELAPSED MULTIPLE MYELOMA (RMM): THE PHASE 3 STUDY ENDEAVOR
Dimopoulos, M.
Moreau, P.
Palumbo, A.
Joshua, D.
Pour, L.
Hajek, R.
Facon, T.
Ludwig, H.
Oriol, A.
Goldschmidt, H.
Rosinol, L.
Straub, J.
Suvorov, A.
Araujo, C.
Rimashevskaya, E.
Pika, T.
Gaidano, G.
Weisel, K.
Goranova-Marinova, V.
Schwarer, A.
Minuk, L.
Masszi, T.
Karamanesht, I.
Offidani, M.
Hungria, V.
Spencer, A.
Gillenwater, H.
Mohamed, N.
Feng, S.
Chng, W. J.
HAEMATOLOGICA, 2015, 100 : 336 - 336
[27] OVERALL SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE RANDOMIZED PHASE 3 ENDEAVOR TRIAL
Dimopoulos, M.
Goldschmidt, H.
Niesvizky, R.
Joshua, D.
Chng, W. -J
Oriol, A.
Orlowski, R.
Feng, S.
Kimball, A.
Moreau, P.
HAEMATOLOGICA, 2017, 102 : 168 - 168
[28] CARFILZOMIB AND LENALIDOMIDE AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: TEMPORARY ANALYSIS OF RESPONSE TO THE HAZARD RATIO FOR PROGRESSION-FREE SURVIVAL
Maria Victoria, Mateos Manteca
Meletios, Dimopoulos A.
Keith, Stewart A.
Michael, Wang
Vladimir, Maisnar
Jiri, Minarik
William, Bensinger, I
Dina, Ben-Yehuda
Vishal, Kukreti
Mihaela, Obreja
Sanjay, Aggarwal
Philippe, Moreau
Antonio, Palumbo
HAEMATOLOGICA, 2016, 101 : 27 - 27
[29] CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF RESPONSE AND PROGRESSION-FREE SURVIVAL HAZARD RATIO OVER TIME
Dimopoulos, M. A.
Stewart, A. K.
Wang, M.
Maisnar, V.
Minarik, J.
Bensinger, W. I.
Mateos, M. V.
Ben-Yehuda, D.
Kukreti, V.
Obreja, M.
Aggarwal, S.
Moreau, P.
Palumbo, A.
HAEMATOLOGICA, 2016, 101 : 83 - 83
[30] GLOBAL SURVIVAL (SG) OF PATIENTS WITH MULTIPLE MYELOMA IN RELAPSED OR REFRACTORY (MMRR) WITH CARFILZOMIB plus DEXAMETHASONE (KD) VS BORTEZOMIB plus DEXAMETHASONE (VD) IN RANDOMIZED PHASE 3 ENDEAVOR STUDY
Oriol, A.
Dimopoulos, M.
Goldschmidt, H.
Niesvizky, R.
Joshua, D.
Chng, W. J.
Orlowski, R. Z.
Feng, S.
Kimball, A. S.
Moreau, P.
HAEMATOLOGICA, 2017, 102 : 19 - 19

← 1 2 3 4 5 →